Category Archives: news

Primetime Special on Cord Blood Stem Cell Therapy

Two cerebral palsy patients and CBR clients who are experiencing positive results after undergoing reinfusion of their own cord blood stem cells were featured on the NBC San Francisco Bay Area show Health Matters: Stem Cell Therapy Today & Tomorrow.

Stem Cells: Developing New Cures

New York Stem Cell Foundation (NYSCF) has helped create a video on stem cell research currently playing in the Hall of Human Origins at the American Museum of Natural History in New York. It portrays the promise of stem cell therapies for human disease and demonstrates the potential of the research to create opportunities for studying disease fundamentals.

Stem Cells: Developing New Cures from NYSCF on Vimeo.

5th Annual Summit to Feature New Stem Cell Therapies

WAYNE, Pa., Jan. 8 /PRNewswire/ — Six new stem cell therapies, all forecast to reach physicians in 2010, will be featured at the 5th Annual Stem Cell Summit on February 16 in New York City. These new therapies include allograft products, innovative forms of autologous stem cell technologies, and at least one FDA-approved stem cell drug. New studies showing rehydration of the disc nucleus, regeneration of new heart muscle and others are also on the agenda.

The Stem Cell Summit is an annual gathering of stem cell and biomaterial company executives, scientists and investors to explore the therapeutic applications of stem cells, the successful path to stem cell product commercialization, and the latest investment opportunities within the space. The Summit features 35 corporate presentations, a scientific panel, separate tracks for stem cell tools & instruments, and a closing reception. It is an intensive one-day event held at Bridgewaters in New York City’s historic South Street Seaport.

The presenting stem cell companies include:

Aastrom Biosciences, Inc.        INCELL Corporation, LLC
AllCells, LLC                            International Stem Cell Corp.
AlloSource                               Lonza Group Ltd.
Aldagen, Inc.                           MaxCyte, Inc.
ArunA Biomedical, Inc.            Mesoblast Limited
Athersys, Inc.                           Novocell, Inc.
BioE Inc.                                   Osiris Therapeutics, Inc.
Cardiogenesis Corp.                 Pluristem Therapeutics Inc.
Cellerix, S.A.                             ProChon Biotech, Ltd.
Celtigen Therapeutics, LLC      Progenitor Cell Therapy, Inc.
Core Dynamics Ltd.                   SpineSmith Partners LP
Cytori Therapeutics, Inc.           Stematix, Inc.
Gamida Cell Ltd.                        Stemina Biomarker Discovery, Inc.
Garnet BioTherapeutics, Inc.    TiGenix NV
Genzyme Biosurgery                  Tissue Genesis, Inc.
Glycosan BioSystems, Inc.         TxCell SA
Harvest Technologies Corp.      Vet-Stem, Inc.
Histogen, Inc.

In addition to the company and scientific presentations, Robin R. Young, CFA, a leading medical technologies analyst, will deliver his updated 10-year market forecast for the industry. “In 2009, the number of new market entrants was notable, but there were some difficulties with regard to clinical trials. Nevertheless, sales of stem cell therapies continue to grow extremely rapidly in the United States. We now estimate that revenues from stem cell therapies will surpass $2.5 billion by 2015 and that the industry will support a $10 billion valuation,” said Young.

5th Annual Stem Cell Summit Facts at a Glance

When:  Tuesday, February 16, 2010

Where:  Bridgewaters
11 Fulton Street
New York City

Admission:  $1,200 advance registration by January 31, 2010
$1,500 (February 1 – 16, 2010)

Information: A detailed agenda and online registration are available at

Life Science Stocks: A Growing Market in 2010

By David Bogoslaw,

What if doctors had a detailed road map of the kinds of drugs and therapies that your own personal genetic makeup makes you most receptive to, instead of having to arrive at effective treatments through the costly — and sometimes painful — method of trial and error? That’s the promise of the nascent field of personalized medicine.

click link above for complete article.

New stem cell treatment holds promise for cerebral palsy patients

By Deborah Takahara,

Dominic King and Harrison Spiers have so much in common. Best friends for seven years, they are both in the 5th grade at Cottonwood Creek Elementary School. They both love to ride horses. They both love to go to baseball games. And both were born with Cerebral Palsy.

“It’s (caused) a lack of oxygen before, during, or right after birth,” Dominic’s mom, Christina King explained. “With Dominic, we don’t know what happened.”

Alicia Spiers, Harrison’s mother, says he can’t feed himself, can’t give himself a bath and can’t take himself to the bathroom.

“It’s just like having a newborn in a 10-year-old’s body,” Spiers told us.

The families tried everything from therapy to experimental procedures, but nothing seemed to be helping. Then, last year, Harrison’s parents asked him what he wanted for Christmas. “I want stem cells,” he told them.

His parents knew right where to turn. They had a friend named Jessie Hinkley, a medical student.

“I taught them about a new procedure being done in Germany where they can take stem cells from the bone marrow from that patient and turn them into brain cells, and then go up to the brain and repair sites that were damaged,” Hinkley said.

Harrison’s father said the procedure is not related to the use of embryonic stem cells.

“There’s been a lot of debate on health care, and stem cells. This is not controversial. They are taking it from (Harrison’s) own body and putting it back in his own body. It’s here and now, not maybe 30 years from now,” he said.

But the procedure is not done in the United States, so the boys would have to raise thousands of dollars and travel to Germany. Fortunately, their school and their community stepped up and made it possible.

“It’s amazing. I know we keep saying that word, but truly is,” Alicia Spears. “(We) hear it everyday on the news?people are being laid off, unemployment numbers are up, money is tight. And yet, people in this neighborhood and this community found a way to write checks.”

“It hit me, I started crying in the car and thought this is just unbelievable what people will do,” Christina King said.

The boys took the trip to Germany and had the stem cell treatment done in August. They were back in time to start the school year, and their families say they’ve already started to see the results.

Dominic is starting to read. Harrison is sitting up by himself. Speaking is getting easier. Their parents don’t know how much to credit the stem cell therapy, but they are convinced it has made a difference.

“I see things almost every day: (Harrison’s) fine motor skills get better, just a little bit more everyday,” Alicia Spiers says. “People used to say ‘hi’ to him and you could count to 10 before he would say ‘hi’ back. Now it’s pretty instant.”

Harrison’s father hopes other people with other disabilities can take advantage of the procedure.

“There’s really no limit to what could happen. That’s the part that’s intoxicating.”

Stem Cells Implantation- A Miracle Cure for Blindness

By Snigdha Taduri for

In a revolutionary experiment, British scientists have discovered a innovative treatment for curing the most common cause for blindness by using a line of patients own embryonic stem cells. Age related macular degeneration is the most common case of blindness in elderly, with at least 300,000 patients being affected every year- a number that is expected to treble in the next 25 years.

The London Project to Cure Blindness is the world’s first blindness therapy that involves replacing damaged retinal cells with stem cells which entailed injecting cells into the back of the eye to replaced damaged photoreceptors – tiny light-sensitive cells found in the retina and key to vision. The key step in the experiment was the selection of slightly more mature stem cells that turned into photoreceptors and formed connections with the nerves leading to the brain.

Most of the transplanted photoreceptors were rod cells that are responsible for vision in the night. It is believed that transplant of cone cells would help enhance viewing of colour and viewing detail. This transplant combination of rod and cone cells would provide an overall enhanced vision to patients.

This premise of this experiment is based on the belief that human retina houses cells that can be used for such transplants. This pioneering stem cell surgery, spearheaded by researchers at the world-famous Moorfields Eye Hospital in London plans to begin clinical trials on humans in two years.

Lyndon da Cruz, a surgeon at Moorfields says the surgery has the potential to become as commonplace as a cataract surgery in a few years time. Tom Bremridge, chief executive of the Macular Disease Society, said: “This is a huge step forward for patients. We are extremely pleased that the big guns have become involved, because, once this treatment is validated, it will be made available to a huge volume of patients.”

Pfizer, the world’s largest pharmaceutical research company, has announced its financial backing to bring the therapy to patients. Pfizer’s role would be crucial in bringing production of the membranes to an industrial level. Professor Coffey, the project leader for the London Project to Cure Blindness commented: “We have not only the benefit of Pfizer’s experience of the regulatory process and their expertise in stem cell technology but the ability, if this works, to produce on a much larger scale.  It has huge implications, not only for our project, but for the field of regenerative medicine as a whole.  And it is great that Britain is at the forefront of this research.”

Protein that keeps stem cells poised for action identified


Scientists from Stanford University School of Medicine have identified a protein that appears to play a critical role in keeping stem cells poised to quickly become more specialised cell types.

The protein called Jarid2 maintains a delicate balancing act – one that both recruits other regulatory proteins to genes important in differentiation and also modulates their activity to keep them in a state of ongoing readiness.

“Understanding how only the relevant genes are targeted and remain poised for action is a hot topic in embryonic stem cell research,” said Dr Joanna Wysocka, assistant professor of developmental biology and of chemical and systems biology.

“Our results shed light on both these questions,” Wysocka added.

Jarid2 works through a protein complex called PRC2, for Polycomb Repressive Complex 2, which is necessary to regulate the expression of developmentally important genes in many types of cells.

According to the researchers, PRC2 activity allows the cell to carefully manage its degree of readiness for the subsequent unwrapping and expression of genes involved in differentiation of the embryonic stem cells into more specialised cells.

“It was just as we would have predicted,” said Wysocka. “Without Jarid2, which keeps the genes silent yet poised for activation, the embryos stop developing.”

The researchers now plan to further investigate the mechanism by which Jarid2 summons PRC2 to differentiation-specific genes in the stem cells, and how it affects gene expression.

The interaction may be important in human cancers as well.

The study appears in journal Cell.

Pioneering stem cell treatment restores sight

By Richard Alleyne,

Russell Turnbull, 38, lost most of the vision in his right eye when he had ammonia sprayed into it as he tried to break up a fight on a late night bus journey home.

The attack, which badly burned and scarred his cornea, left him with permanent blurred sight and pain whenever he blinked.

Now however his sight has been almost fully restored thanks to a new technique where doctors regrow the outside membrane of his cornea from stem cells taken from his healthy eye.

The new operation involves cutting away a millimetre squared section of his left eye complete with stem cells and growing it to 400 times that size in the laboratory.

The new outer skin of the eye is then stitched onto the badly damaged cornea in place of the damaged membrane.

The technique, developed by scientists and eye surgeons at the North East England Stem Cell Institute (NESCI). has been used on eight patients and for most of them including Mr Turnbull it has almost completely restored their vision.

Dr Francisco Figueiredo, Consultant Eye Surgeon at NESCI team, who co-led the project, said: “Corneal cloudiness has been estimated to cause blindness in eight million people worldwide each year.

“The stem cell treatment option is aimed at total cure rather than symptom relief only. This new treatment will alleviate patient suffering and remove the need for long term multiple medications as well as returning the patient to functional and social independence.”

Dr Sajjad Ahmad, who developed the Newcastle method for culturing limbal stem cells, said “This study shows that stem cell research conducted in the laboratory can have a major impact on the quality of life of patients with corneal disease. This work has been a team effort involving stem cell researchers and hospital doctors working together effectively.”

A larger study involving 24 new patients is currently underway with funding from the UK’s Medical Research Council.

Mr Turnbull, a storeman, said: “The operation was a complete success and I now have my sight back. This really has given me my life back.”

Details of the treatment have been published in the American journal, Stem Cells.

Stem Cells Save Legs

From Ivanhoe Newswire

Two million people in the United Sates suffer from critical limb ischemia, or poor blood flow to their legs. As the number of diabetics soars, the number of those affected is expected to almost double by 2020. The condition causes severe pain and chronic infection. Surgery to open blocked veins is often the treatment, but for 40 percent of patients it doesn’t work and they lose their leg to amputation. Now, doctors are turning to a patient’s own body to heal itself.

Cathy Ballzigler doesn’t take one moment of her life for granted. A few years ago, she came close to losing it.

“He told my husband that I was about 11 weeks from dying,” Ballzigler told Ivanhoe.

Ballzigler was losing feeling in her leg. Her doctor said it was critical limb ischemia. The arteries in her leg were blocked. A year of surgeries didn’t help, and she was told amputation was her last resort.

“He really wanted to take my leg off, but I would beg and plead and say don’t take it off, just do what you can,” Ballzigler said.

“They’ll often have unresolving wounds — wounds that just will not heal because they don’t have the blood supply to the tissues,” George Geils, Jr., M.D., medical director of the Blood and Marrow Transplant Program at Roper St. Francis Healthcare in Charleston, S.C., told Ivanhoe.

An experimental 20-minute procedure is helping patients who’ve run out of options. Doctors remove stem cells from the pelvic bone and inject them back into the leg along the course of the diseased artery.

“If you take those stem cells out and put them into another organ, they can actually function and grow a different tissue in the body,” Dr. Geils said.

After four to six weeks, new arteries start to grow.

“I went from 17 percent oxygen to over 66 percent oxygen after my surgery,” Ballzigler said.

Today, she toasts to her future and is thankful for a second chance.

Smoking, diabetes and high blood pressure put patients at risk for critical limb ischemia. The stem cell treatment costs less than conventional limb-saving procedures like bypass surgery and stents.

See Related Article:
Bioheart Makes Breakthrough In Critical Limb Ischemia Therapy With Stem Cells Obtained From Fat Tissue

Stem cell therapies for hearts inching closer to wide use

By Elizabeth Landau,

If you’ve just had your first heart attack, doctors may one day be able to reverse the damage done with stem cell therapy.

An intravenous method of injecting stem cells into patients who had experienced heart attacks within the previous 10 days suggested that this method works to repair — not just manage — heart damage, a recent study found.

The study is a step forward in a field in which a lot of approaches have been tried in animals and preliminary human trials, but none has been approved for widespread clinical use for heart patients.

The new results are a milestone in stem cell research, and for patients, said Jeffrey Karp, a researcher at Brigham and Women’s Hospital in Boston, Massachusetts, who runs a stem cell biology lab at Harvard University. He was not involved in the study.

Most current clinical approaches are focused on managing problems, not addressing the root of the damage, he said.

“Many patients who have a heart attack will go on to suffer heart failure,” he said. “It’s imperative to try and fix the root of the problem as quickly as possible.”

The research, published in the Journal of the American College of Cardiology, were part of a phase I study that set out to show safety. The trial has moved on to phase II, which is taking place in 50 hospitals in the United States, said Dr. Joshua Hare, director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine and lead author of the study.

“We’re looking on the time frame here of five years, in the best-case scenario, to have approved cardiac stem cell therapies,” Hare said.

Coronary heart disease, which causes heart attacks and angina — chest pain resulting from the heart not getting enough blood — is the leading cause of death in the United States, with nearly 450,000 in 2005, according to the American Heart Association. About 1.1 million people have attacks occur in the United States each year, according to the National Heart Lung and Blood Institute.

The particular kind of cells used in this research are called mesenchymal stem cells, and come from adults, not embryos.

The researchers are using a mesenchymal stem cell therapy that is marketed by Osiris Therapeutics Inc. under the name Prochymal. The drug, which consists of stem cells from donor bone marrow, gets injected into the vein. The cells then travel through the bloodstream and take up residence in the heart.

Mesenchymal stem cells have some natural homing capability, and injury serves as a homing beacon for them, Karp said.

The stem cells reduce the amount of scar tissue and increase the pumping strength of the heart in heart attack patients, Hare said. To a limited extent, they also grow new heart muscle.

The phase I results from 53 patients are not definitive proof that the treatment is effective, but do suggest so, Hare said. In accordance with clinical trial regulations set by the Food and Drug Administration, phase I is meant to show safety, while phase II and phase III trials are done on a larger group of subjects and evaluate how well the drug works.

In this trial, patients’ doses ranged from 35 million cells to 350 million cells. There was no change or increase in side effects in treatments getting higher doses of cells, but it seemed that the treatment was more effective — at least in terms of reducing electrical problems — in the high dose group, he said.

In separate trials, researchers are looking at how the technique works in patients who have had heart attacks many month or years in the past, Hare said.

The study shows the results of a six-month follow-up with patients in 2007, and researchers are presently working with data from the two-year follow-up.

More broadly, besides bone marrow transplantations, there have not been any major successes in the stem cell field in terms of helping large numbers of patients, Karp said.

“Mesenchymal stem cells are poised to really be the next major success in cell therapy that could be used to treat tens of thousands of patients,” he said.

There are several advantages to using mesenchymal stem cells for heart therapy. First, they are adult stem cells, so there are no ethical issues that surround research on embryonic stem cells. Secondly, at least from a safety perspective, mesenchymal stem cells do not require matching — any donor can give cells to any other donor, and no immunosuppresant drugs are necessary, he said.

Still, millions of cells are required in order for enough stem cells to reach the heart and have a therapeutic benefit, and it’s costly to get the required numbers of cells for each patient, Karp said. An area of improvement would be making the stem cell treatment more efficient, he said.

“If we could increase the number of cells that could reach the heart, that would have significant advantages to this approach,” Karp said.

This method of intravenous injection means that the procedure theoretically could be performed in a doctor’s office or clinic, increasing the accesibility to patients, Karp said.

A more invasive stem cell delivery technique has been showing positive results in other clinical trials, involving injecting patients’ own stem cells directly into heart muscle.

The largest national stem cell study for heart disease, sponsored by Baxter Inc., uses this surgical method, and recently announced success in a 12-month phase II trial for patients with severe angina. Researchers found that participants had less pain and an improved ability to walk.

Because stem cells are delivered through a catheter in this method, there is a risk of perforation of about 1 percent, Dr. Douglas Losordo, cardiologist at Northwestern Memorial Hospital in Chicago, Illinois, told CNN earlier this year. The drug, GCSF, which mobilizes stem cells, also carries a small risk of blood clotting.

For the Osiris trials, further research is ongoing determine whether patients would benefit more from more infusions of the stem cells, or if it’s better for the stem cells to come from their own bodies instead of from a donor, Hare said.

While there’s less chance of a person’s body rejecting his or her own stem cells than from a donor, there is a time delay, he said. Taking bone marrow and amplifying the stem cells in it could take up to five weeks, whereas donor cells could be made readily available, he said. On the other hand, it is unclear whether a donor could potentially transmit a disease to the recipient in the process.

If you are interested in enrolling in a clinical trial, you can find one at  The Orisis trial is still recruiting participants.